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Previewsderived. The nonresponse of the ER and
ER+ tumors when treated with the BH-3
mimetics alone indicates these agents
are less likely to be effective in tumors
that show de novo resistance
to endocrine therapy, which might, for
example, depend on ER-independent
mechanisms. Rather, they would be ex-
pected to extend the speed, degree, and
duration of the response of those tumors
that are at least partially responsive.
Although it would have been reassuring
to see a similar enhancement of response
to estrogen deprivation with the BH3
mimetics, and this could have been
achieved by using low-dose estrogen
pellets, there is no compelling reason to
believe that the effects would be tamox-
ifen specific. Nonetheless, the authors
made one observation that was both
interesting and potentially helpful that is
specific to tamoxifen: ABT-737 counter-
acted tamoxifen-induced endometrial
hyperplasia, which was associated with
a profound increase in apoptotic activity
and cleaved caspase-3 positive cells,
suggesting the effects of tamoxifen in
inducing this deleterious effect may relate
to BCL-2.
In the two ER+ breast cancer models
used by Vaillant et al. (2013) that exhibited
only a partial response to the BH3-mi-metics plus tamoxifen, increased expres-
sion of phosphorylated AKT was evident.
The PI3K/AKT/mTOR pathway is
frequently activated in breast cancer (Pol-
yak and Metzger Filho, 2012) and strongly
associated with the ligand-independent
activation of ER (Ali and Coombes, 2002)
and resistance to endocrine therapy.
Furthermore, AKT modulates phosphory-
lation of BAD, suppressing its proapopto-
tic function. Asmight be expected, target-
ing the xenografts with a dual PI3K/mTOR
inhibitor in combination with ABT-737 and
tamoxifen proved superior to the mono or
dual therapies. Thus, although the
concern is expressed above that endo-
crine resistant tumors are likely to prove
resistant to combination with anti-BCL-2
agents, this might not be the case if the
mechanism of that resistance was itself
also targeted.
Lastly, in the clinic, ER+ tumors have
been found to show a reduced likelihood
of complete pathological eradication
with chemotherapy or anti-HER2 thera-
pies than ER tumors. The antagonism
of BCL-2 in these ER+ tumors might
enhance the effectiveness of these pre-
dominately proapoptotic treatments
even more than it does in these encour-
aging data from combination with endo-
crine therapies.CancerREFERENCES
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Tumor metastasis is the primary cause of death due to cancer, but the mechanisms by which tumor cells
metastasize remain incompletely understood. In this issue of Cancer Cell, Schumacher and colleagues sug-
gest that ATP released from tumor-associated platelets in the blood facilitates tumor metastasis by relaxing
endothelial barrier function.Just as countries need to protect their
borders for the purposes of national secu-
rity, so too must tissues maintain properborders for normal function. During
metastasis, tissue borders are breached
as cancer cells move from their place oforigin to distant organs, where their
growth may lead to tissue dysfunction.
Although most cancer patients die fromCell 24, July 8, 2013 ª2013 Elsevier Inc. 9
Figure 1. Tumor Cell Metastasis Is Facilitated by Platelet-Derived
ATP
Circulating tumor cells associate with and activate blood platelets. Tumor-
associated platelets release ATP from their dense granules, which act on
endothelial P2Y2 receptors to relax endothelial cell junctions, thereby enabling
tumor cells to successfully exit the bloodstream and enter the tissue to form a
new metastasis. (Figure courtesy of Dr. Stefan Offermanns and colleagues;
reproduced from the online graphical abstract of Schumacher et al., 2013,
http://dx.doi.org/10.1016/j.ccr.2013.05.008.)
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Previewsmetastases rather than their
primary tumor, the molecular
underpinnings of cancer
spread have remained
elusive. Addressing this
knowledge gap has been
challenging because each
step in the so-called ‘‘meta-
static cascade’’—invasion,
bloodstream entry, extrava-
sation, and growth at a distant
site—is rare and inefficient
(Talmadge and Fidler, 2010).
In this issue of Cancer Cell,
the study by Schumacher
et al. (2013) describes a new
molecular pathway by which
platelets, the clot-forming
cells of the blood, can serve
as cellular ‘‘coyotes,’’ smug-
gling tumor cells across intact
blood-tissue borders.
A relationship between can-
cer and clot formationwas first
recognized by French physi-cian Armand Trousseau, who noted in
1865 that patients with internal malig-
nanciesoftenpresentedwith thrombophle-
bitis (‘‘phlegmasia alba dolens’’) (Trous-
seau, 1865). Trousseau realized that
the site of blood clotting could be far from
the tumor and suspected that ‘‘a special
alteration of the blood’’ was responsible.
The clinical significance of this association
was demonstrated shortly afterward
when Trousseau used it to diagnose his
own terminal gastric cancer. However,
nearly 150 years later, the mechanism(s)
and biological importance of this special
alteration of the blood remain complex
and mysterious.
Platelets are small, anuclear cells that
circulate in theblood in very highnumbers.
Circulating platelets are quiescent, but in
the setting of a vessel injury, they become
activated by exposure to collagen, the
coagulation protease thrombin, and other
molecules not normally present in the
blood. Activated platelets drive thrombus
formation by creating shear-resistant
aggregates, supporting coagulation
factor activation and further thrombin
generation, and releasing vasoactive and
prothrombotic agents from intracellular
granules. Elevated platelet numbers have
been associated with tumor metastasis
and poor prognosis clinically for over a
century (reviewed in (Erpenbeck and
Schon, 2010). A causal role for platelets10 Cancer Cell 24, July 8, 2013 ª2013 Elseviin mediating cancer spread was first
revealed when mice treated with neur-
aminidase exhibited a marked reduction
in tumormetastasis due to an unexpected
drop in their platelet counts (Gasic et al.,
1968). More recent genetic studies have
confirmed this observation, establishing
that both reduced platelet numbers
and reduced platelet activation can
dramatically inhibit tumor metastasis in
mice (Camerer et al., 2004; Palumbo
et al., 2005). Thus, platelet activation
appears to be a key component of
Trousseau’s proposed ‘‘special alteration
of the blood.’’
How do platelets support tumor metas-
tasis? Because platelets do not leave the
bloodstream, they must help tumor cells
survive in the blood environment and/or
exit the bloodstream. One idea is that
platelets may act as protective ‘‘cloaks’’
for circulating tumor cells (CTCs), shielding
them from immune destruction. During
passage in the blood, tumor cells are
exposed to natural killer (NK) cells that
are capable of directly lysing them. Deple-
tion of NK cells negates the protective
effect of platelets during hematogenous
metastasis in mice (Nieswandt et al.,
1999). Further supporting this model,
impairments in platelet activation due to
the loss of Gaq or impaired thrombus for-
mation due to the lack of fibrinogen lead
to a reduced rate of metastasis only whener Inc.NK cells are present (Palumbo
et al., 2005). Platelet and
endothelial cell adhesion pro-
teins may also facilitate
metastasis by augmenting
tumor cell extravasation, a
hypothesis supported by the
observation that tumormetas-
tases are reduced in mice
lacking the vascular adhesion
molecules P- and L-selectin
(Wahrenbrock et al., 2003).
More recently, genetic studies
have demonstrated that
platelet activation and release
of transforming growth factor
b may enhance metastasis
by inducing epithelial tumor
cells to convert to a mesen-
chymal phenotype that facili-
tates tumor cell extravasation
and tissue invasion (Labelle
et al., 2011). These and other
studies reveal a complex
scenario in which activatedplatelets facilitate metastasis through
numerous mechanisms.
In this issue ofCancer Cell, Schumacher
et al. (2013) reveal a novel mechanism by
which platelets facilitate tumor metastasis
in a manner independent of their role
in clotting. To discover platelet-derived
agents that might facilitate tumor cell
extravasation from the blood, the authors
studied the effects of activated platelet su-
pernatant on tumor cell migration through
an endothelial monolayer. These studies
identified platelet-dense granule-derived
ATP as a potent facilitator of tumor cell
endothelial transmigration. To test the
role of platelet-derived ATP in tumor
metastasis, the authors employed animals
lacking Munc 13-4, an exocytosis priming
protein that is required for platelets to
release their dense granules but is
dispensable for all other platelet functions.
Munc 13-4-deficient platelet supernatant
was unable to facilitate tumor cell transmi-
gration in vitro. Importantly, implantationof
B16F10 melanoma and Lewis lung carci-
noma cells into Munc 13-4-deficient mice
resulted in a dramatic reduction in lung
metastases while having no effect on
primary tumor growth.
The authors then used their endothelial
transmigration assay to identify P2Y2 as
the ATP receptor most likely to mediate
platelet-assisted tumor cell transmig-
ration and confirmed this role in vivo using
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specific conditional deletion studies were
not done, radiation chimeras confirmed
that Munc 13-4 is required in circulating
cells and P2Y2 in non-hematopoietic cells
for these effects. These elegant studies
support a molecularly straightforward
model in which activated platelets associ-
ated with CTCs release ATP, which then
acts on endothelial P2Y2 receptors to
reduce endothelial barrier function and
facilitate tumor cell movement out of the
blood (Figure 1).
One of the most exciting aspects of this
study is that it provides ‘‘actionable intelli-
gence’’ in the form of a set of molecular
targets that could potentially be used to
tighten tissue border security in patients
with cancer. While wholesale blockade of
platelet activation and/or adhesion might
reduce tumor metastasis, it would also
increase the risk of bleeding. The study
by Schumacher et al. (2013) suggests
that the P2Y2 receptor might provide a
means of attacking platelet-promoted
metastasis without disabling normal
platelet hemostatic function. P2Y2 recep-
tors have diverse roles in vivo in many
cell types, but the knockout mice are
relatively healthy, and the related P2Y12purinergic receptor is the target of a num-
ber of successful drugs. These character-
istics identify P2Y2 as an attractive drug
target to block tumor metastasis, but
going forward, it will be important to
determine whether the current findings
apply solely to implantable melanoma
and lung carcinoma cell lines or whether
Munc 13-4/P2Y2 inhibition also works
more generally in genetically engineered
models.
A larger question, not addressed by this
study, is what patient population would
benefitmost fromanti-metastatic therapy?
If a tumor is detected prior to metastasis,
then surgical removal of the tumor would
be a preferable and more definitive way
of preventing spread. However, if metas-
tasis has already occurred, even at the
microscopic level, how will reducing
further tumor cell extravasation at that
point lead to an improved outcome? As
with any issue of border control, there will
be debate concerning the best approach.
But before even considering such ques-
tions, it is necessary to know what makes
borders porous and what can be done to
plug the holes; the work of Schumacher
et al. (2013) provides an important new
piece of that basic knowledge.Cancer CREFERENCES
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Androgen deprivation therapy (ADT) for advanced prostate cancer inexorably leads to resistance, and
clinically useful biomarkers are lacking. The value of genetically engineered mice for coclinical studies
is clearly demonstrated in a recent publication that reveals XAF1, XIAP, and SRD5A1 as novel predictive
biomarkers and therapeutic targets for ADT resistance.The mainstay of therapy for metastatic
prostate cancer for more than 70 years
has been systemic androgen ablation,
which was aimed at suppressingandrogen receptor (AR)-mediated sig-
naling as a growth and survival pathway
for prostate cancer cells (Huggins and
Hodges, 1941). The discovery that ARsignaling remains active in castration-
resistant prostate cancers (CRPCs)
(Chen et al., 2004) led to the introduction
of novel antiandrogen therapies, namelyell 24, July 8, 2013 ª2013 Elsevier Inc. 11
